Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and raises the price target from $52 to $62.
July 01, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on PTC Therapeutics and increased the price target from $52 to $62, indicating a positive outlook on the stock.
The increase in price target from $52 to $62 by a reputable analyst firm like Cantor Fitzgerald suggests a strong positive outlook for PTC Therapeutics. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100